|Bid||247.38 x 1000|
|Ask||258.87 x 1300|
|Day's Range||252.51 - 259.10|
|52 Week Range||176.36 - 292.75|
|Beta (5Y Monthly)||0.61|
|PE Ratio (TTM)||31.01|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With the COVID-19 crisis sending the U.S. economy in a recession, we're looking at what companies managed to thrive during the last recession for guidance.
On Tuesday, Vertex Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. Keep an eye out to see if VRTX stock sees more buying action from institutional investors. The new Composite score means the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
You may be spending a little more time than you'd like these days thinking about a future market crash. But instead of letting the recent stock-market decline scare us, we should let it help us: Let's use it as a reminder that market corrections and crashes will happen.